Story perspectives

Intismeran Plus Keytruda Extends Melanoma Recurrence-Free Survival

8/24/2026

Summary

Story summary

Moderna and Merck reported that intismeran plus Keytruda extended recurrence-free survival in a Phase 3 melanoma trial.
The combination also lengthened distant metastasis-free survival compared with Keytruda alone.
No new safety concerns emerged, though detailed side-effect data remain unpublished.
Moderna shares jumped 177% to $174.38, adding $45 billion market value, while Merck stock rose 26%.
Analysts project 2032 intismeran sales could reach $1.4 billion, 17% higher than prior forecasts.

1 of 1

Story summary

Moderna and Merck reported that intismeran plus Keytruda extended recurrence-free survival in a Phase 3 melanoma trial.
The combination also lengthened distant metastasis-free survival compared with Keytruda alone.
No new safety concerns emerged, though detailed side-effect data remain unpublished.
Moderna shares jumped 177% to $174.38, adding $45 billion market value, while Merck stock rose 26%.
Analysts project 2032 intismeran sales could reach $1.4 billion, 17% higher than prior forecasts.